CANNABIS
Dronabinol increases pain threshold compared to placebo for functional chest pain over 4 weeks
Dis Esophagus. 2017 Feb 1;30(2):1-8. doi: 10.1111/dote.12455Thirteen patients with non-cardiac functional chest pain were randomized to receive 5 mg capsules of dronabinol or placebo twice daily for 4 weeks. Patients described their chest pain episodes, completed the Short Form-36 (SF-36), Beck Anxiety Inventory and Beck Depression Inventory, and rated their pain during esophageal balloon distention tests (EBDT) to determine if dronabinol increased pain thresholds. Results indicate that dronabinol patients had significantly increased pain thresholds during the EBDT for certain pressures compared to baseline and placebo. Beck Anxiety and Depression Inventories and SF-36 were not significantly different between groups, and adverse effects were mild or moderate. A significant percentage of patients in each group were excluded due to noncompliance.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
